About: NT5E CpG island methylation is a favourable breast cancer biomarker     Goto   Sponge   Distinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Relapse risk assessment and individual treatment recommendations remain suboptimal for breast cancer patients. In the light of existing preclinical and clinical data, we studied NT5E (5'-nucleotidase, ecto) expression and NT5E CpG island methylation in breast cancer. METHODS: We used RT-PCR, qPCR, methylation-specific PCR and pyrosequencing to analyse NT5E in breast carcinoma cell lines and primary and breast carcinomas. RESULTS: NT5E CpG island methylation was inversely associated with NT5E expression in breast carcinoma cell lines. In clinical series, patients whose primary tumours had NT5E CpG island methylation were less likely to develop metastasis (P = 0.003, OR = 0.34, 95% CI: 0.17-0.69). In 3/4 paired samples, NT5E was methylated in primary tumours and demethylated in CNS metastases. Patients progressing to non-visceral as compared with visceral metastases were more likely to have NT5E CpG island methylation in primary tumours (P = 0.01, OR = 11.8). Patients with tumours lacking detectable methylation had shorter disease-free survival (DFS) (P = 0.001, HR = 2.7) and overall survival (OS) (P 0.001, HR 3). The favourable prognostic value of NT5E methylation was confirmed in oestrogen receptor negative (P = 0.011, HR = 3.27, 95% CI: 1.31-8.12) and in triple negative cases (P = 0.004; HR = 6.2, 95% CI: 1.9-20). Moreover, we observed a more favourable outcome to adjuvant chemotherapy in patients whose tumours were positive for NT5E CpG island methylation: DFS (P = 0.0016, HR = 5.1, 95% CI: 1.8-14.37) and OS (P = 0.0005, HR = 7.4, 95% CI: 2.416-23.08). CONCLUSION: NT5E CpG island methylation is a promising breast cancer biomarker.
  • Relapse risk assessment and individual treatment recommendations remain suboptimal for breast cancer patients. In the light of existing preclinical and clinical data, we studied NT5E (5'-nucleotidase, ecto) expression and NT5E CpG island methylation in breast cancer. METHODS: We used RT-PCR, qPCR, methylation-specific PCR and pyrosequencing to analyse NT5E in breast carcinoma cell lines and primary and breast carcinomas. RESULTS: NT5E CpG island methylation was inversely associated with NT5E expression in breast carcinoma cell lines. In clinical series, patients whose primary tumours had NT5E CpG island methylation were less likely to develop metastasis (P = 0.003, OR = 0.34, 95% CI: 0.17-0.69). In 3/4 paired samples, NT5E was methylated in primary tumours and demethylated in CNS metastases. Patients progressing to non-visceral as compared with visceral metastases were more likely to have NT5E CpG island methylation in primary tumours (P = 0.01, OR = 11.8). Patients with tumours lacking detectable methylation had shorter disease-free survival (DFS) (P = 0.001, HR = 2.7) and overall survival (OS) (P 0.001, HR 3). The favourable prognostic value of NT5E methylation was confirmed in oestrogen receptor negative (P = 0.011, HR = 3.27, 95% CI: 1.31-8.12) and in triple negative cases (P = 0.004; HR = 6.2, 95% CI: 1.9-20). Moreover, we observed a more favourable outcome to adjuvant chemotherapy in patients whose tumours were positive for NT5E CpG island methylation: DFS (P = 0.0016, HR = 5.1, 95% CI: 1.8-14.37) and OS (P = 0.0005, HR = 7.4, 95% CI: 2.416-23.08). CONCLUSION: NT5E CpG island methylation is a promising breast cancer biomarker. (en)
Title
  • NT5E CpG island methylation is a favourable breast cancer biomarker
  • NT5E CpG island methylation is a favourable breast cancer biomarker (en)
skos:prefLabel
  • NT5E CpG island methylation is a favourable breast cancer biomarker
  • NT5E CpG island methylation is a favourable breast cancer biomarker (en)
skos:notation
  • RIV/00064173:_____/12:43906998!RIV13-MZ0-00064173
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • I
http://linked.open...iv/cisloPeriodika
  • 1
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 154929
http://linked.open...ai/riv/idVysledku
  • RIV/00064173:_____/12:43906998
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • triple-negative breast cancer; epigenetics; metastasis; breast cancer (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV
  • [847E6CAF2E2B]
http://linked.open...i/riv/nazevZdroje
  • British Journal of Cancer
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 107
http://linked.open...iv/tvurceVysledku
  • Gojiš, Ondřej
http://linked.open...ain/vavai/riv/wos
  • 000305888400012
issn
  • 0007-0920
number of pages
http://bibframe.org/vocab/doi
  • 10.1038/bjc.2012.212
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 82 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software